Home› Procurement News - Fda grants accelerated approval to gileads hepcludex(r) (bulevirtide-gmod), the first and only approved treatment for chronic hepatitis delta virus (hdv), United states (533228971)

An invitation to bid has been published by for Fda grants accelerated approval to gileads hepcludex(r) (bulevirtide-gmod), the first and only approved treatment for chronic hepatitis delta virus (hdv) in United states. The tender closing date is 24 May 2026.

Procurement News

Procurement News
News TI Ref No
533228971
News Date
24 May 2026
News Description
Fda grants accelerated approval to gileads hepcludex(r) (bulevirtide-gmod), the first and only approved treatment for chronic hepatitis delta virus (hdv)
Tender Deadline
⏰ 24 May 2026 Closing soon
News Project Location
United States
News Sector
Healthcare and Medical Tenders
News Document Type
Procurement News
Tender Organization Name
🔒 Members only Click for more details
Unlock Full Details — Register Free
Start with receiving Free Data Samples related to your Products and Services
✓
Live Tender Updates from worldwide
✓
Access to original Tender Documents
✓
Information on Upcoming Projects & Contract Awards
✓
Bid Assistance Services
✓
Competitor Analysis & Industry Trends
✓
Daily Custom Email Alerts by Sector & Country

Similar News

View All Healthcare and Medical Tenders Tenders ->

Register to View Tenders

Start Your Business Journey. Register now for 3 days Free Sample Tenders & AI Website Demo.

Already have an account? Login here

By registering you agree to our Terms & Conditions and Privacy Policy.